首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Clinical cancer research

缩写:CLIN CANCER RES

ISSN:1078-0432

e-ISSN:1557-3265

IF/分区:10.9/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引11950条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Zelei Yang,Upendra Raj Bhattarai,Martin K Hayes et al. Zelei Yang et al.
Purpose: CDK4/6 inhibitors (CDK4/6is) are being investigated in endometrial cancer (EC) clinical trials with some patients showing a significant response. However, there are few biomarkers to predict which EC patients wil...
Pablo Jimenez-Labaig,Oriol Mirallas,Charleen Chan Wah Hak et al. Pablo Jimenez-Labaig et al.
Xevinapant, an antagonist of inhibitor of apoptosis proteins (IAPs) from the SMAC-mimetic drug class, was developed to restore apoptosis in cancer cells. Preclinical studies demonstrated on-target IAP degradation, caspase activation, and pr...
Aman Chauhan,Heidi L Weiss,Charles Kunos et al. Aman Chauhan et al.
Introduction: Next generation of Theranostics studies are looking at novel combinations with radiation sensitizers to enhance PRRT's efficacy. Here, we present safety and efficacy data from a multi-center phase 1 study of...
Natalie I Vokes,Jessica L Symons,Brooke Rhead et al. Natalie I Vokes et al.
Introduction: Homozygous deletion of 9p21, containing CDKN2A/B and MTAP (CMdel), underlies emerging therapeutic strategies including PRMT5/MAT2A inhibition. The clinicogenomic context and treatment outcomes of CMdel in NS...
Atsushi Horiike,Hiroshi Wakui,Shunichi Sugawara et al. Atsushi Horiike et al.
Purpose: This study investigated the efficacy and safety of pembrolizumab and necitumumab as first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) who had ≥50% programmed death-ligand 1 (PD-L1)...
Michael F Maloney,Justina X Caushi,Lenore A Cullen et al. Michael F Maloney et al.
Purpose: Targeting intracellular oncogenic mutations with T-cell engagers has the potential to expand precision immunotherapy beyond surface antigens. Here, we describe the preclinical characterization of CLSP-1025, a mut...
Shozo Okamoto,Kaori Nomura,Tohru Shiga et al. Shozo Okamoto et al.
Purpose: The efficacy of current therapeutic options for pheochromocytomas and paragangliomas, such as 131I-meta-iodobenzylguanidine (131I-MIBG), is limited owing to low complete response rates and a requirement for prolo...
Zev A Wainberg,Keun-Wook Lee,Jong Gwang Kim et al. Zev A Wainberg et al.
Purpose: DeFianCe was a randomized phase 2 study evaluating sirexatamab, a Dickkopf-related protein 1 (DKK1)-neutralizing antibody, plus chemotherapy and bevacizumab as second-line therapy for metastatic colorectal cancer...
Noushin Niknafs,Lavanya Sivapalan,Archana Balan et al. Noushin Niknafs et al.
Purpose: Circulating tumor DNA (ctDNA) analyses are informative as an early indicator of immunotherapy response in advanced non-small cell lung cancer (NSCLC); however, the clinical value of ctDNA molecular response requi...
Sarina A Piha-Paul,Chih-Yi Liao,Farshid Dayyani et al. Sarina A Piha-Paul et al.
Purpose: Tinengotinib, a multikinase inhibitor targeting Aurora kinases A/B, fibroblast growth factor receptors (FGFRs) 1-3, vascular endothelial growth factor receptor-2, and Janus kinases 1-2, was evaluated in this phas...